Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study

Giovanni Tortorella, Andrea Piccin, Alessia Tieghi, Luigi Marcheselli, Michael Steurer, Günther Gastl, Katia Codeluppi, Angelo Fama, Umberto Santoro, Chiara Birtolo, Gabriele Gugliotta, Sergio Cortelazzo, Luigi Gugliotta

Research output: Contribution to journalArticlepeer-review


In this prospective observational single-center study, 55 patients with essential thrombocythemia who were candidates for second line treatment with anagrelide (ANA) received a preliminary cardiovascular (CV) clinical, instrumental and biochemical evaluation (CV history and symptoms, CV risk factors, blood pressure, heart rate, ECG and ECHO-cardio parameters, Troponin I, NT-proBNP). After this in-depth CV screening, 54 out of 55 patients were deemed to be fit for ANA treatment. Thirty-eight of the 55 patients received ANA treatment for a median of 36 months (range 3-48), and were monitored using the same CV evaluation. Fourteen of these 38 patients manifested CV adverse events (10 palpitation, 4 edema, 2 arterial hypertension, 2 acute myocardial infarction) that were not predicted by the in-depth CV evaluation, and that led to ANA withdrawal in only one case (non-cardiac refractory edema). In conclusion, the planned in-depth CV evaluation did not appear to be necessary in ET patients to evaluate their suitability for ANA treatment, and, moreover, was not able to predict the occurrence of CV adverse events during ANA treatment. Nevertheless, the CV adverse events (mostly palpitations and edema) were easily managed by the hematologists, and required the cardiologist involvement in very few selected cases.

Original languageEnglish
Pages (from-to)592-598
Number of pages7
JournalLeukemia Research
Issue number6
Publication statusPublished - Jun 1 2015


  • Anagrelide
  • Cardiovascular adverse events
  • Cardiovascular evaluation
  • Edema
  • Essential thrombocythemia
  • Palpitation

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study'. Together they form a unique fingerprint.

Cite this